SGLT2抑制剂对胰岛β细胞的保护作用及潜在机制  

Protective effects and potential mechanism of the SGLT2 inhibitor on islet β cells

作　　者：王康丽 洪天配[1] 魏蕊[1] Wang Kangli;Hong Tianpei;Wei Rui(Department of Endocrinology and Metabolism,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院内分泌科,100191

出　　处：《中华内分泌代谢杂志》2021年第4期297-300,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金(81830022、81770768、81970671)。

摘　　要：保护胰岛β细胞是糖尿病治疗的重要策略。新型降糖药物钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂通过抑制肾小管对葡萄糖的重吸收来降低血糖,该降糖作用不依赖胰岛素。多项临床研究发现,该类药物可明显改善β细胞功能。动物研究显示,SGLT2抑制剂可增加β细胞总量。SGLT2抑制剂促进β细胞再生有以下几种方式:促进β细胞增殖、抑制β细胞凋亡和去分化、促进α细胞向β细胞转化及诱导前体细胞来源的β细胞新生。降糖、减重、改善血脂谱等机体代谢改善的间接作用、抑制炎症反应、促进胰岛α细胞分泌GLP-1、调控胰岛基因表达等可能介导了SGLT2抑制剂对β细胞的保护。Isletβcell protection is one of the key strategies for diabetes treatment.The new antidiabetic drug sodium-glucose cotransporter 2(SGLT2)inhibitor decreases blood glucose by inhibiting glucose reabsorption in the renal tubule,independent of insulin.Various clinical studies have shown that SGLT2 inhibitors improveβcell function.Furthermore,animal experiments have indicated that SGLT2 inhibitors increaseβcell mass.SGLT2 inhibitors promote islet regeneration through stimulatingβcell proliferation,inhibitingβcell apoptosis and dedifferentiation,enhancing transdifferentiation ofαcells toβcells,and initiating progenitor-derivedβcell neogenisis.Indirect effects of metabolic improvement(i.e.lowering glucose,losing weight,improving lipid metabolism),inhibiting inflammatory reaction,inducing glucagon-like peptide-1 secreted fromαcells,and regulating gene changes might be involved in theβcell protection of SGLT2 inhibitors.

关 键 词：胰岛再生 钠-葡萄糖协同转运蛋白2抑制剂 胰岛Β细胞功能 糖尿病 

分 类 号：R965[医药卫生—药理学]